Suvoda's Innovative Solutions Propel a New Era in Clinical Trials for Patients and Sites
In the ever-evolving landscape of clinical research, Suvoda has emerged as a trailblazer committed to enhancing the clinical trial experience for patients and research sites alike. In 2025, the company's strategic merger with Greenphire stood as a milestone, highlighting its ambition to unify and simplify clinical operations.
The merger aimed at tackling the longstanding operational challenges faced in clinical trials reflects Suvoda's vision to craft a more integrated approach. As a result, the company has consolidated its strengths, leveraging the technologies and expertise of both Suvoda and Greenphire. This integration is not merely corporate; it is about creating a cohesive ecosystem that reduces complexity throughout the clinical trial lifecycle.
"The last year has marked significant progress for Suvoda," said CEO Jagath Wanninayake. His reiteration of the company’s focus on aligning technologies and teams indicates a pivotal shift in how they plan to assist sponsors and sites in navigating the complexities of clinical trials. With a unified mission, 2026 takes shape as a year of potential and growth.
One of the crowning achievements of the past year is the launch of Suvoda's patient app. This application is a clear demonstration of Suvoda's commitment to elevating the patient experience. By integrating electronic Clinical Outcome Assessments (eCOA), patient payments, reminders, and scheduling into a singular, user-friendly platform, Suvoda has facilitated engagement for participants while alleviating the administrative burden on research sites. For patients, this means a simpler, streamlined process that empowers them to manage their involvement in trials more effectively.
Additionally, Suvoda has harnessed the power of artificial intelligence through the introduction of Sofia, an AI assistant designed to enhance information accessibility for study teams. Rather than navigating through multiple systems, users can pose questions and receive immediate, clear answers, thus facilitating daily decision-making. With privacy and role-based controls firmly in place, Sofia also maintains data security and the integrity of study protocols while optimizing efficiency.
Suvoda's innovations did not go unnoticed in 2025, as it received a new patent for its platform architecture, bringing its total to five. Its remarkable strides earned it recognition as a Leader in the RTSM PEAK Matrix® assessment conducted by Everest Group. The enhancements introduced across its suite of services have consistently improved transparency, data quality, and usability, underscoring its commitment to practical innovation that resonates with real-world needs.
As we look toward 2026, Suvoda anticipates sustained growth, driven by the increasing demand among pharmaceutical sponsors and contract research organizations (CROs) for comprehensive platforms that simplify trials while enhancing patient and site experiences. "We spent 2025 merging not just companies, but technologies and missions,” stated Wanninayake. This strong foundation is set to propel Suvoda into a future where it can deliver even greater value and efficiency.
Headquartered just outside Philadelphia, Suvoda is recognized globally for its real-time clinical trial technology solutions. It empowers sponsors and CROs with software that allows for informed decision-making while supporting the patient experience through dedicated, responsive service. With a history of high customer satisfaction and engagement across more than 2000 clinical trials in over 95 countries, Suvoda is primed for impactful advancements in clinical research.
The merger with Greenphire signifies not just an expansion of services but a transformation in how clinical trials are conducted, ultimately aiming to create more effective, patient-centric research environments. For more information on Suvoda and its innovative offerings, visit suvoda.com and connect with Suvoda on LinkedIn.
Merging for Greater Impact
The merger aimed at tackling the longstanding operational challenges faced in clinical trials reflects Suvoda's vision to craft a more integrated approach. As a result, the company has consolidated its strengths, leveraging the technologies and expertise of both Suvoda and Greenphire. This integration is not merely corporate; it is about creating a cohesive ecosystem that reduces complexity throughout the clinical trial lifecycle.
"The last year has marked significant progress for Suvoda," said CEO Jagath Wanninayake. His reiteration of the company’s focus on aligning technologies and teams indicates a pivotal shift in how they plan to assist sponsors and sites in navigating the complexities of clinical trials. With a unified mission, 2026 takes shape as a year of potential and growth.
Enhancing the Patient Experience
One of the crowning achievements of the past year is the launch of Suvoda's patient app. This application is a clear demonstration of Suvoda's commitment to elevating the patient experience. By integrating electronic Clinical Outcome Assessments (eCOA), patient payments, reminders, and scheduling into a singular, user-friendly platform, Suvoda has facilitated engagement for participants while alleviating the administrative burden on research sites. For patients, this means a simpler, streamlined process that empowers them to manage their involvement in trials more effectively.
Artificial Intelligence at the Core
Additionally, Suvoda has harnessed the power of artificial intelligence through the introduction of Sofia, an AI assistant designed to enhance information accessibility for study teams. Rather than navigating through multiple systems, users can pose questions and receive immediate, clear answers, thus facilitating daily decision-making. With privacy and role-based controls firmly in place, Sofia also maintains data security and the integrity of study protocols while optimizing efficiency.
Recognition and Future Growth
Suvoda's innovations did not go unnoticed in 2025, as it received a new patent for its platform architecture, bringing its total to five. Its remarkable strides earned it recognition as a Leader in the RTSM PEAK Matrix® assessment conducted by Everest Group. The enhancements introduced across its suite of services have consistently improved transparency, data quality, and usability, underscoring its commitment to practical innovation that resonates with real-world needs.
As we look toward 2026, Suvoda anticipates sustained growth, driven by the increasing demand among pharmaceutical sponsors and contract research organizations (CROs) for comprehensive platforms that simplify trials while enhancing patient and site experiences. "We spent 2025 merging not just companies, but technologies and missions,” stated Wanninayake. This strong foundation is set to propel Suvoda into a future where it can deliver even greater value and efficiency.
About Suvoda
Headquartered just outside Philadelphia, Suvoda is recognized globally for its real-time clinical trial technology solutions. It empowers sponsors and CROs with software that allows for informed decision-making while supporting the patient experience through dedicated, responsive service. With a history of high customer satisfaction and engagement across more than 2000 clinical trials in over 95 countries, Suvoda is primed for impactful advancements in clinical research.
The merger with Greenphire signifies not just an expansion of services but a transformation in how clinical trials are conducted, ultimately aiming to create more effective, patient-centric research environments. For more information on Suvoda and its innovative offerings, visit suvoda.com and connect with Suvoda on LinkedIn.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.